Log in to save to my catalogue

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_adb752a8ee7a42218b15e9daa8e28b17

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma

About this item

Full title

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma

Publisher

Switzerland: MDPI AG

Journal title

Pharmaceuticals (Basel, Switzerland), 2023-12, Vol.17 (1), p.25

Language

English

Formats

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established therapeutic concepts. Recent de...

Alternative Titles

Full title

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_adb752a8ee7a42218b15e9daa8e28b17

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_adb752a8ee7a42218b15e9daa8e28b17

Other Identifiers

ISSN

1424-8247

E-ISSN

1424-8247

DOI

10.3390/ph17010025

How to access this item